Pancreatic beta cells and islets

Pancreatic islets, or islets of Langerhans, are specialized clusters of endocrine cells within the pancreas that play a fundamental role in regulating systemic metabolism (StatPearls, NBK542252). The most prominent cell type within these islets is the beta cell, which serves as the body's primary glucose sensor and the sole site of insulin synthesis and secretion (PubMed, PMC6054484). Under normal physiological conditions, beta cells respond to elevated blood glucose by releasing insulin, which facilitates glucose uptake in muscle and adipose tissues to maintain homeostasis (NIH, "The Pancreas and Insulin"). In Type 1 diabetes, these cells are the target of autoimmune destruction, leading to a total loss of insulin production, while in Type 2 diabetes, they undergo progressive dysfunction and failure due to chronic metabolic stress and insulin resistance (Nature Reviews Endocrinology, 2017). While many anti-diabetic drugs, such as sulfonylureas and GLP-1 receptor agonists, act directly on beta cell receptors to modulate insulin output, the islets themselves are considered a complex tissue system rather than a discrete molecular target. Consequently, therapeutic research often focuses on preserving beta cell mass or regenerating islet function to treat various forms of diabetes (PubMed, PMC7284575).

Other names

Islets of LangerhansBeta cellsPancreatic isletsIslet cells

Pharmacological agents do not target the islet as a single entity but interact with specific molecular targets within the beta cells. Sulfonylureas and meglitinides bind to the sulfonylurea receptor 1 (SUR1) subunit of ATP-sensitive potassium (K-ATP) channels to induce membrane depolarization and insulin release (StatPearls, NBK551568). Incretin mimetics, such as GLP-1 receptor agonists, bind to the glucagon-like peptide-1 receptor (GLP-1R) to enhance glucose-dependent insulin secretion and promote beta cell survival (PubMed, PMC6054484).